Understanding how to improve immune responses against hepatitis B virus
Official title: Hepatic Priming of CD4+ T cells Directs Effective Hepatitis B Virus Immunity
Funded at University of California, San Francisco · NIH-11090325 · Data updated 2026-11-12
This study is looking at how kids and adults respond to the hepatitis B virus and aims to find ways to help the body fight off the virus better, with the hope of creating new treatments that can help people clear the virus and avoid serious liver problems.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | March 15, 2024 |
| Project end | March 14, 2027 |
| Funding year | 2025 |
| Award (this year) | $47,203 |
| NIH project number | 5F31DK135386-02 |
| Project ID | NIH-11090325 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with chronic hepatitis B infection, particularly those who have not responded well to current treatments.
✕Less likely to help
Patients who have cleared the hepatitis B virus or those with other liver diseases unrelated to HBV may not benefit from this research.
What this research studies
This research investigates the differences in immune responses to hepatitis B virus (HBV) between children and adults, focusing on how to enhance the body's ability to clear the virus. By using a mouse model that mimics human HBV infections and analyzing existing data from clinical trials, the study aims to identify key factors that influence the effectiveness of the immune response. The goal is to develop new therapies that can help patients achieve HBsAg seroclearance, which is crucial for preventing severe liver disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enable patients to clear hepatitis B virus from their systems, reducing the risk of liver disease and cancer.
How similar studies have gone: Previous research has shown promise in understanding immune responses to hepatitis B, but this approach is innovative in its direct comparison of mouse and human data.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Carey, Nicholas Daniel — University of California, San Francisco
- Study coordinator: Carey, Nicholas Daniel
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.